The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Alberts, A. W., Chen, J., Kuron, G., Hunt, V, Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,628
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
ENDO, A., KURODA, M., & TSUJITA, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Clearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Self-citationPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Self-citationContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Self-citationMyopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450010075034 · Cited by 428
Lovastatin decreases coenzyme Q levels in humans.
Folkers, K., Langsjoen, P., Willis, R., Richardson, P., Xia, L. J., Ye, C. Q., & Tamagawa, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.8931 · Cited by 426
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Kobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Self-citationNeuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Self-citationFichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., Alston, B., Fang, F., Kosel, B., & Aweeka, F. (2002) · AIDS · doi:10.1097/00002030-200203080-00008 · Cited by 338
EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336
Self-citationGemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Lilja, J. J., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90130-8 · Cited by 312
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., & Wacher, V. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00034-6 · Cited by 292
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 287
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90034-0 · Cited by 276
(1997) · PubMed · Cited by 271
Hoffman, W. F., Alberts, A. W., Anderson, P. S., Chen, J. S., Smith, R. L., & Willard, A. K. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00155a040 · Cited by 266
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
Self-citationDifferent effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin
Sugimoto, K., Ohmori, M., Tsuruoka, S., Nishiki, K., Kawaguchi, A., Harada, K., Arakawa, M., Sakamoto, K., Masada, M., Miyamori, I., et al. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)64092-x · Cited by 247
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
LILJA, J., KIVISTO, K., & NEUVONEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90048-6 · Cited by 241
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Sasaki, M., Suzuki, H., Ito, K., Abe, T., & Sugiyama, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109081200 · Cited by 228
Self-citationCITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B
Satoh, H., Yamashita, F., Tsujimoto, M., Murakami, H., Koyabu, N., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002337 · Cited by 225
Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events
Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 224
Recent Advances in Carrier-mediated Hepatic Uptake and Biliary Excretion of Xenobiotics
Yamazaki, M., Suzuki, H., & Sugiyama, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016077517241 · Cited by 221
Self-citationNakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T., & Nishimura, K. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29609-9 · Cited by 217
Saheki, A., Terasaki, T., Tamai, I., & Tsuji, A. (1994) · Pharmaceutical Research · doi:10.1023/a:1018975928974 · Cited by 206
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
White, C. M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127000204200902 · Cited by 199
Biotransformation of lovastatin
Wang, R. W., Kari, P. H., Lu, A. Y. H., Thomas, P. E., Guengerich, F. P., & Vyas, K. P. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90551-s · Cited by 196
Clinically relevant differences between the statins: implications for therapeutic selection
Chong, P. H., Seeger, J. D., & Franklin, C. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00870-1 · Cited by 196
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
Kivistö, K. T., Niemi, M., Schaeffeler, E., Pitkälä, K., Tilvis, R., Fromm, M. F., Schwab, M., Eichelbaum, M., & Strandberg, T. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114762.78957.a5 · Cited by 193
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085589 · Cited by 190
Self-citationGemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189
Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
Lilja, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110216 · Cited by 187
Dresser, G. K., Kim, R. B., & Bailey, D. G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.005 · Cited by 186
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084830 · Cited by 181
Self-citationLaaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Wang, E.-J., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 176
Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers
Tse, F. L. S., Jaffe, J. M., & Troendle, A. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb05773.x · Cited by 175
Transon, C., Leemann, T., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050094 · Cited by 173
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Kivistö, K. T., Kantola, T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00034.x · Cited by 171
Koga, T., Shimada, Y., Kuroda, M., Tsujita, Y., Hasegawa, K., & Yamazaki, M. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90139-o · Cited by 168
Olbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., & ROOTS, I. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70104-9 · Cited by 158
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
Lilja, J. J., Neuvonen, M., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02095.x · Cited by 157
PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS
Iwatsubo, T., Hirota, N., Ooie, T., SUZUKI, H., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199605)17:4<273::aid-bdd961>3.0.co;2-r · Cited by 154
Self-citationYamazaki, M., Suzuki, H., Hanano, M., Tokui, T., Komai, T., & Sugiyama, Y. (1993) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1993.264.1.g36 · Cited by 152
Self-citationIto, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 151
Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Self-citationJohnson, T. E., Zhang, X. D., Bleicher, K. B., Dysart, G. R., Loughlin, A. F., Schaefer, W. H., & Umbenhauer, D. R. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.010 · Cited by 144
Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 144
Self-citationHsyu, P., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 144
Hasegawa, M., Kusuhara, H., Sugiyama, D., Ito, K., Ueda, S., Endou, H., & Sugiyama, Y. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.746 · Cited by 141
Self-citationMichalski, C. W., Cui, Y., Nies, A. T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M. F., KEPPLER, D. O. R., & König, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207735200 · Cited by 140
Lau, Y. Y., Okochi, H., Huang, Y. L., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093088 · Cited by 140
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini, S., Bon, G., Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06052-2 · Cited by 140
Yamazaki, M., Akiyama, S., Ni'inuma, K., Nishigaki, R., & Sugiyama, Y. (1997) · PubMed · doi:10.7270/q2cr5vmx · Cited by 140
Self-citationÁrnadóttir, M., Eriksson, L.-O., Thysell, H., & Karkas, J. D. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187521 · Cited by 137
Mazzu, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110537 · Cited by 136
Clinical Pharmacokinetics of Cerivastatin
ck, W. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00002 · Cited by 135
Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I., & Brockmöller, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00121-8 · Cited by 135
Flint, O. P., Masters, B. A., Gregg, R. E., & Durham, S. K. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8131 · Cited by 132
Ichimaru, N., Takahara, S., Kokado, Y., Wang, J. D., Hatori, M., Kameoka, H., Inoue, T., & Okuyama, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00438-5 · Cited by 130
Åsberg, A., Hartmann, A., Fjeldså, E., Bergan, S., & Holdaas, H. (2001) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2001.10415.x · Cited by 127
Isolated Mitochondrial Myopathy Associated With Muscle Coenzyme Q10 Deficiency
Lalani, S. R., Vladutiu, G. D., Plunkett, K., Lotze, T. E., Adesina, A. M., & Scaglia, F. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.317 · Cited by 127
Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions
Crespi, C. L., & Penman, B. W. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60205-7 · Cited by 125
Use of statins in CNS disorders
Cucchiara, B. L., & Kasner, S. E. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00529-9 · Cited by 125
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Cooper, K. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17633-8 · Cited by 115
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
Siedlik, P. H., Olson, S. C., Yang, B., & Stern, R. H. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900510 · Cited by 110
Kajinami, K., Brousseau, M. E., Ordovás, J. M., & Schaefer, E. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.078 · Cited by 109
Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin
Hochman, J. H., Pudvah, N. T., Qiu, J., Yamazaki, M., Tang, C., Lin, J. H., & Prueksaritanont, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041466.84653.8c · Cited by 109
Lü, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M., & Rodrigues, A. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1352 · Cited by 109
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid
Uçar, M., Neuvonen, M., Luurila, H., Dahlqvist, R., Neuvonen, P. J., & Mj�rndal, T. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0700-5 · Cited by 107
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*
Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 105
Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
POGSON, G. W., Kindred, L. H., & Carper, B. G. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00034-x · Cited by 105
Pharmacokinetics of the combination of fluvastatin and gemfibrozil
Spence, J. D., Muñoz, C. E., Hendricks, L., Latchinian, L., & Khouri, H. E. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80024-4 · Cited by 102
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
White, C. M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401102876 · Cited by 100
Holdgate, G. A., Ward, W. H. J., & McTaggart, F. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310528 · Cited by 98
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
Fujino, H., Saito, T., Tsunenari, Y., Kojima, J., & Sakaeda, T. (2004) · Xenobiotica · doi:10.1080/00498250400015319 · Cited by 98
Roberts, M. S., & Rowland, M. (1986) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01106707 · Cited by 98
Grundy, S. M. (1955) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1955.tb49338.x · Cited by 97
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01720.x · Cited by 97
Morimoto, K., Oishi, T., Ueda, S., Ueda, M., Hosokawa, M., & Chiba, K. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.453 · Cited by 96
Fujino, H., Yamada, I., Shimada, S., Yoneda, M., & Kojima, J. (2003) · Xenobiotica · doi:10.1080/0049825021000017957 · Cited by 96
Kajinami, K., Takekoshi, N., Brousseau, M. E., & Schaefer, E. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.004 · Cited by 92
Takeda, M., Noshiro, R., Onozato, M. L., Tojo, A., Hasannejad, H., Huang, X.-L., Narikawa, S., & Endou, H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.017 · Cited by 89
Simvastatin‐Nelfinavir Interaction Implicated in Rhabdomyolysis and Death
Hare, C. B., Vu, M., Grünfeld, C., & Lampiris, H. W. (2002) · Clinical Infectious Diseases · doi:10.1086/344179 · Cited by 88
van Vliet, A. K., van Thiel, G. C. F., Huisman, R. H., Moshage, H. J., Yap, S. H., & Cohen, L. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)00176-y · Cited by 87
Proton-Cotransport of Pravastatin Across Intestinal Brush-Border Membrane
Tamai, I., Takanaga, H., Maeda, H. A., Ogihara, T., Yoneda, M., & Tsuji, A. (1995) · Pharmaceutical Research · doi:10.1023/a:1016269806840 · Cited by 86
Pharmacokinetics of Fluvastatin and Specific Drug Interactions
Smith, H. T., Jokubaitis, L. A., Troendle, A. J., Hwang, D.-Y., & Robinson, W. T. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.375s · Cited by 86
Goldberg, R., & Roth, D. (1996) · Transplantation · doi:10.1097/00007890-199612150-00005 · Cited by 85
Pang, K. S., & Gillette, J. R. (1978) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31406-0 · Cited by 85
Ishigami, M., Honda, T., Takasaki, W., Ikeda, T., Komai, T., Ito, K., & Sugiyama, Y. (2001) · PubMed · Cited by 84
Self-citationROGERS, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101208 · Cited by 84
Rhabdomyolysis associated with lovastatin and erythromycin use.
Spach, D. H., Bauwens, J. E., Clark, C. D., & Burke, W. G. (1991) · PubMed Central · Cited by 81
Wang, A., Yu, B., Luo, C., Tan, Z., Zhou, G., Wang, L., Zhang, W., Li, Z., Liu, J., & Zhou, H. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0848-7 · Cited by 80
Tokui, T., Nakai, D., Nakagomi, R., Yawo, H., Abe, T., & Sugiyama, Y. (1999) · Pharmaceutical Research · doi:10.1023/a:1018838405987 · Cited by 79
Self-citationPark, J., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaroß, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600404 · Cited by 78
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
Kyrklund, C., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01972.x · Cited by 77
Tissue selectivity of hydroxymethylglutaryl coenzyme a (HMG CoA) reductase inhibitors
Sirtori, C. R. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90031-8 · Cited by 77
Lovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and Azithromycin
Grunden, J. W., & Fisher, K. A. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100710 · Cited by 75
Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
深澤, 一., Uchida, N., Uchida, E., & Yasuhara, H. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02030.x · Cited by 74
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
Gadbut, A. P., Caruso, A. P., & Galper, J. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(95)92163-x · Cited by 68
Yamazaki, M., Akiyama, S., Nishigaki, R., & Sugiyama, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016044032571 · Cited by 65
Self-citationHMG-CoA Reductase Inhibitors for Hypercholesterolemia
(1988) · New England Journal of Medicine · doi:10.1056/nejm198811033191811 · Cited by 64
Rhabdomyolysis due to probable interaction between simvastatin and ritonavir
Cheng, C. H., Miller, C., Lowe, C., & Pearson, V. E. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.8.728 · Cited by 63
Primary active transport of organic anions on bile canalicular membrane in humans
Niinuma, K., Kato, Y., Suzuki, H., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., & Sugiyama, Y. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.276.5.g1153 · Cited by 61
Self-citationAmsden, G. W., Kuye, O., & Wei, G. C. G. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011373 · Cited by 60
Ishikawa, C., Ozaki, H., Nakajima, T., Ishii, T., Kanai, S., ANJO, S., Shirai, K., & Inoue, I. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0188-6 · Cited by 60
Yamazaki, M., Kobayashi, K., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199611)17:8<645::aid-bdd986>3.0.co;2-l · Cited by 55
Self-citationMück, W. M., Ochmann, K., Rohde, G., Unger, S., & Kuhlmann, J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050408 · Cited by 53
Simvastatin and lovastatin, but not pravastatin, interact with MDR1
Sakaeda, T., Takara, K., Kakumoto, M., Ohmoto, N., Nakamura, T., Iwaki, K., Tanigawara, Y., & Okumura, K. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778493 · Cited by 52
Updated clinical safety experience with fluvastatin
Jokubaitis, L. A. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90628-9 · Cited by 51
Effect of itraconazole on cerivastatin pharmacokinetics
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050566 · Cited by 49
Efficacy of statin therapy: possible effect of phenytoin
Murphy, M. J., & Dominiczak, M. H. (1999) · Postgraduate Medical Journal · doi:10.1136/pgmj.75.884.359 · Cited by 48
Yamazaki, M., Tokui, T., Ishigami, M., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199612)17:9<775::aid-bdd990>3.0.co;2-s · Cited by 47
Self-citationEvaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.
Ishigami, M., Tokui, T., KOMAI, T., Tsukahara, K., Yamazaki, M., & Sugiyama, Y. (1995) · Pharmaceutical Research · doi:10.1023/a:1016226024587 · Cited by 43
Self-citationInhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia.
Barth, J. D., Kruisbrink, O. A., & Dijk, A. L. V. (1990) · BMJ · doi:10.1136/bmj.301.6753.669-a · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Vlahakos, D., Manginas, A., Chilidou, D., Zamanika, C. G., & Alivizatos, P. A. (2002) · Transplantation · doi:10.1097/00007890-200206270-00022 · Cited by 37
Appel, S., Rüfenacht, T., Kalafsky, G., Tetzloff, W., Kállay, Z., Hitzenberger, G., & Kutz, K. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80012-8 · Cited by 37
Kivist, K. T., Zukunft, J., Hofmann, U., Niemi, M., Rekersbrink, S., Schneider, S., Luippold, G., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0948-z · Cited by 35
Tissue selective drug delivery utilizing carrier-mediated transport systems
Tsuji, A. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00043-7 · Cited by 35
Kikuchi, R., Kusuhara, H., Abe, T., Endou, H., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071621 · Cited by 34
Self-citationMiyauchi, S., Sawada, Y., Iga, T., Hanano, M., & Sugiyama, Y. (1993) · Pharmaceutical Research · doi:10.1023/a:1018952709120 · Cited by 33
Self-citationMathew, P. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.11.125 · Cited by 32
Fujino, H., Yamada, I., Shimada, S., & Kojima, J. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.449 · Cited by 27
Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin
Kahri, A. J., Valkonen, M. M., Vuoristo, M., & Pentikäinen, P. J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d243 · Cited by 27
Muscle Coenzyme Q: A Potential Test for Mitochondrial Activity and Redox Status
Miles, L., Miles, M. V., Tang, P., Horn, P. S., Wong, B. L. Y., deGrauw, T. J., Morehart, P. J., & Bove, K. E. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.01.009 · Cited by 26
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
Morimoto, K., Ueda, S., Seki, N., IGAWA, Y., KAMEYAMA, Y., Shimizu, A., Oishi, T., Hosokawa, M., Iesato, K., & Mori, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.081 · Cited by 25
Trieu, J., Emmett, L., Perera, C., Thanakrishnan, K., & der Wall, H. V. (2004) · Clinical Nuclear Medicine · doi:10.1097/00003072-200412000-00008 · Cited by 25
Pharmacological Comparison of the Statins
Klotz, U. E. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297156 · Cited by 24
Peters, T. K., Mehra, M. R., & Muratti, E. N. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.340s · Cited by 21
Fujino, H., Saito, T., Y. Tsunenari, & Kojima, J. (2004) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2004.20.1-2.25 · Cited by 19
Yachi, K., Harashima, H., Kikuchi, H., SUDO, R., Yamauchi, H., EBIHARA, K., Matsuo, H., Funato, K., & Kiwada, H. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199610)17:7<607::aid-bdd977>3.0.co;2-l · Cited by 19
Statin response and pharmacokinetics variants
Kajinami, K., Masuya, H., Hoshiba, Y., Takeda, K., Sato, R., Okabayashi, M., & Schaefer, E. J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.8.1291 · Cited by 14
Cited by
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
The National Heart, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401520 · Cited by 537
Metadata
- Authors
- Shitara, Y., & Sugiyama, Y.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 112
- Issue
- 1
- Pages
- 71-105
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2018126221
- Cited by
- 576
- References
- 185
- FWCI
- 32.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.